Live Earnings Conference Call: MiNK Therapeutics will host a live Q1 2026 earnings call on May 15, 2026 at 8:30AM ET. Get details.

MiNK Therapeutics (INKT) Competitors

$10.51 -0.54 (-4.89%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$11.16 +0.65 (+6.14%)

As of 05/14/2026 07:52 PM Eastern

Compare

INKT vs. FTFT, MDWD, TKNO, CNTX, and JMAC

Should you buy MiNK Therapeutics stock or one of its competitors? MarketBeat compares MiNK Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiNK Therapeutics include Future FinTech Group (FTFT), MediWound (MDWD), Alpha Teknova (TKNO), Context Therapeutics (CNTX), and Maxpro Capital Acquisition (JMAC).

How does MiNK Therapeutics compare to Future FinTech Group?

MiNK Therapeutics (NASDAQ:INKT) and Future FinTech Group (NASDAQ:FTFT) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Future FinTech Group shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by company insiders. Comparatively, 1.5% of Future FinTech Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MiNK Therapeutics has a net margin of 0.00% compared to Future FinTech Group's net margin of -120.63%. MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-139.00%
Future FinTech Group	-120.63%	-127.23%	-92.11%

In the previous week, MiNK Therapeutics had 4 more articles in the media than Future FinTech Group. MarketBeat recorded 6 mentions for MiNK Therapeutics and 2 mentions for Future FinTech Group. Future FinTech Group's average media sentiment score of 0.43 beat MiNK Therapeutics' score of 0.38 indicating that Future FinTech Group is being referred to more favorably in the news media.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Future FinTech Group	Neutral

MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Future FinTech Group has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market.

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 233.02%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Future FinTech Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Future FinTech Group has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Future FinTech Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.97	N/A
Future FinTech Group	$3.83M	1.67	-$4.62M	-$53.52	N/A

Summary

MiNK Therapeutics beats Future FinTech Group on 10 of the 16 factors compared between the two stocks.

How does MiNK Therapeutics compare to MediWound?

MiNK Therapeutics (NASDAQ:INKT) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MiNK Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -140.80%. MiNK Therapeutics' return on equity of 0.00% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-139.00%
MediWound	-140.80%	-65.79%	-30.16%

In the previous week, MiNK Therapeutics had 4 more articles in the media than MediWound. MarketBeat recorded 6 mentions for MiNK Therapeutics and 2 mentions for MediWound. MediWound's average media sentiment score of 0.63 beat MiNK Therapeutics' score of 0.38 indicating that MediWound is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiNK Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, MediWound has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 233.02%. MediWound has a consensus price target of $35.00, suggesting a potential upside of 108.33%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe MiNK Therapeutics is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

MiNK Therapeutics has higher earnings, but lower revenue than MediWound. MediWound is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.97	N/A
MediWound	$16.96M	12.73	-$23.88M	-$2.10	N/A

Summary

MiNK Therapeutics beats MediWound on 10 of the 16 factors compared between the two stocks.

How does MiNK Therapeutics compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Alpha Teknova presently has a consensus price target of $8.00, suggesting a potential upside of 115.05%. MiNK Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 233.02%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

MiNK Therapeutics has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$41.80M	4.77	-$17.26M	-$0.32	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.97	N/A

In the previous week, MiNK Therapeutics had 2 more articles in the media than Alpha Teknova. MarketBeat recorded 6 mentions for MiNK Therapeutics and 4 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 0.41 beat MiNK Therapeutics' score of 0.38 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Teknova	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiNK Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiNK Therapeutics has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. MiNK Therapeutics' return on equity of 0.00% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
MiNK Therapeutics	N/A	N/A	-139.00%

Alpha Teknova has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 12.5% of Alpha Teknova shares are owned by insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

MiNK Therapeutics beats Alpha Teknova on 9 of the 14 factors compared between the two stocks.

How does MiNK Therapeutics compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Context Therapeutics presently has a consensus price target of $6.60, suggesting a potential upside of 183.26%. MiNK Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 233.02%. Given MiNK Therapeutics' higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Context Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.97	N/A

In the previous week, Context Therapeutics had 11 more articles in the media than MiNK Therapeutics. MarketBeat recorded 17 mentions for Context Therapeutics and 6 mentions for MiNK Therapeutics. Context Therapeutics' average media sentiment score of 1.01 beat MiNK Therapeutics' score of 0.38 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiNK Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiNK Therapeutics' return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
MiNK Therapeutics	N/A	N/A	-139.00%

Context Therapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Context Therapeutics beats MiNK Therapeutics on 8 of the 13 factors compared between the two stocks.

How does MiNK Therapeutics compare to Maxpro Capital Acquisition?

MiNK Therapeutics (NASDAQ:INKT) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, MiNK Therapeutics had 6 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 6 mentions for MiNK Therapeutics and 0 mentions for Maxpro Capital Acquisition. MiNK Therapeutics' average media sentiment score of 0.38 beat Maxpro Capital Acquisition's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Maxpro Capital Acquisition	Neutral

MiNK Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 233.02%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe MiNK Therapeutics is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-139.00%
Maxpro Capital Acquisition	N/A	N/A	N/A

MiNK Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.97	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

MiNK Therapeutics beats Maxpro Capital Acquisition on 8 of the 10 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INKT vs. The Competition

Export

Metric	MiNK Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.05M	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-3.54	18.47	20.89	25.63
Price / Sales	N/A	294.87	549.88	76.62
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	-3.47	6.93	9.93	6.97
Net Income	-$12.49M	$24.11M	$3.55B	$333.62M
7 Day Performance	-4.80%	5.89%	1.70%	1.09%
1 Month Performance	-18.78%	-0.91%	0.49%	3.08%
1 Year Performance	41.07%	74.58%	39.41%	35.68%

MiNK Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INKT MiNK Therapeutics	2.5176 of 5 stars	$10.51 -4.9%	$35.00 +233.0%	+40.1%	$55.05M	N/A	N/A	30	News Coverage Analyst Downgrade
FTFT Future FinTech Group	0.6805 of 5 stars	$1.30 +4.0%	N/A	-80.9%	$6.55M	$3.83M	N/A	70	Upcoming Earnings Short Interest Increase
MDWD MediWound	2.1026 of 5 stars	$16.57 -4.1%	$35.00 +111.2%	-13.5%	$221.96M	$16.96M	N/A	80	News Coverage
TKNO Alpha Teknova	2.437 of 5 stars	$3.83 -4.3%	$8.00 +108.9%	-42.9%	$214.44M	$41.80M	N/A	240
CNTX Context Therapeutics	3.4635 of 5 stars	$2.38 +2.1%	$6.60 +177.3%	+194.9%	$214.08M	N/A	N/A	7	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INKT) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, MDWD, TKNO, CNTX, and JMAC

How does MiNK Therapeutics compare to Future FinTech Group?

Summary

How does MiNK Therapeutics compare to MediWound?

Summary

How does MiNK Therapeutics compare to Alpha Teknova?

Summary

How does MiNK Therapeutics compare to Context Therapeutics?

Summary

How does MiNK Therapeutics compare to Maxpro Capital Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, MDWD, TKNO, CNTX, and JMAC

How does MiNK Therapeutics compare to Future FinTech Group?

Do institutionals & insiders hold more shares of INKT or FTFT?

Is INKT or FTFT more profitable?

Does the media refer more to INKT or FTFT?

Which has more volatility and risk, INKT or FTFT?

Do analysts prefer INKT or FTFT?

Which has stronger valuation & earnings, INKT or FTFT?

Summary

How does MiNK Therapeutics compare to MediWound?

Do insiders and institutionals hold more shares of INKT or MDWD?

Is INKT or MDWD more profitable?

Does the media prefer INKT or MDWD?

Which has more risk and volatility, INKT or MDWD?

Do analysts rate INKT or MDWD?

Which has higher valuation and earnings, INKT or MDWD?

Summary

How does MiNK Therapeutics compare to Alpha Teknova?

Do analysts rate TKNO or INKT?

Which has better valuation & earnings, TKNO or INKT?

Does the media prefer TKNO or INKT?

Is TKNO or INKT more profitable?

Which has more volatility & risk, TKNO or INKT?

Do institutionals and insiders hold more shares of TKNO or INKT?

Summary

How does MiNK Therapeutics compare to Context Therapeutics?

Do analysts rate CNTX or INKT?

Which has better valuation & earnings, CNTX or INKT?

Does the media prefer CNTX or INKT?

Is CNTX or INKT more profitable?

Which has more volatility & risk, CNTX or INKT?

Do institutionals and insiders hold more shares of CNTX or INKT?

Summary

How does MiNK Therapeutics compare to Maxpro Capital Acquisition?

Do institutionals & insiders hold more shares of INKT or JMAC?

Does the media refer more to INKT or JMAC?

Do analysts prefer INKT or JMAC?

Is INKT or JMAC more profitable?

Which has more risk & volatility, INKT or JMAC?

Which has higher earnings & valuation, INKT or JMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools